Chemours Co (CC) Stock Analysis
Verdict: AVOID
Heavy PFAS litigation liabilities and $4.12B debt wall outweigh low sales multiples, leaving CC highly speculative despite insider buys.
Investment score: 36/100
Analysis as of
Is Chemours Co stock worth reviewing? AI model thesis
Chemours carries extreme balance sheet leverage ($4.12B debt) and negative total equity (-$48M), rendering low revenue multiples unappealing against ongoing PFAS legal settlement cash drains.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 20/100 (weight 15%)
- Technical Momentum: 25/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 75/100 (weight 10%)
- Analyst Consensus: 60/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
Chemours Co opportunities and risks
What speaks for CC
- Opteon low-GWP refrigerant demand in AI data center cooling
What speaks against CC
- Balance sheet insolvency and negative stockholders equity
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CC | n/a | 0.4x | n/a | 15.3% | -5.2% | 6.1% |
| HUN | n/a | 0.3x | 13.0x | 13.5% | -2.9% | -0.6% |
| LXU | 19.8x | 1.1x | 7.7x | 17.3% | 5.6% | 23.1% |
| Peer median | 5.6x | 0.7x | 10.3x | 15.4% | 1.3% | 11.3% |
Frequently asked questions about Chemours Co (CC)
Is CC stock a good investment?
The cached TradeMates AI model rates Chemours Co as AVOID with an investment score of 36/100. Chemours carries extreme balance sheet leverage ($4.12B debt) and negative total equity (-$48M), rendering low revenue multiples unappealing against ongoing PFAS legal settlement cash drains. This is algorithmic model output, not personal investment advice.
Is CC stock a buy?
The TradeMates model verdict for CC is AVOID with an investment score of 36/100. Treat this as a model signal to review, not a personal buy recommendation.